A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
Clinical trial NCT02087059 · COMPLETED
Trial details
- NCT number
- NCT02087059
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-04-01
- Primary completion
- 2015-03-01
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.